Doriano Fabbro
DecImmune Therapeutics (United States)(US)NBE Therapeutics (Switzerland)(CH)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Protein Kinase Regulation and GTPase Signaling, Eosinophilic Disorders and Syndromes
Most-Cited Works
- → The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY(2017)1,645 cited
- → Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl(2005)1,480 cited
- → Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity(2008)1,147 cited
- → The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands(2015)1,040 cited
- → Trends in kinase drug discovery: targets, indications and inhibitor design(2021)738 cited
- → The Concise Guide to PHARMACOLOGY 2015/16: Enzymes(2015)603 cited